These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 33434356)

  • 1. Dual Agonist of Farnesoid X Receptor and Takeda G Protein-Coupled Receptor 5 Inhibits Hepatitis B Virus Infection In Vitro and In Vivo.
    Ito K; Okumura A; Takeuchi JS; Watashi K; Inoue R; Yamauchi T; Sakamoto K; Yamashita Y; Iguchi Y; Une M; Wakita T; Umezawa K; Yoneda M
    Hepatology; 2021 Jul; 74(1):83-98. PubMed ID: 33434356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist.
    Rizzo G; Passeri D; De Franco F; Ciaccioli G; Donadio L; Rizzo G; Orlandi S; Sadeghpour B; Wang XX; Jiang T; Levi M; Pruzanski M; Adorini L
    Mol Pharmacol; 2010 Oct; 78(4):617-30. PubMed ID: 20631053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity.
    Shimura S; Watashi K; Fukano K; Peel M; Sluder A; Kawai F; Iwamoto M; Tsukuda S; Takeuchi JS; Miyake T; Sugiyama M; Ogasawara Y; Park SY; Tanaka Y; Kusuhara H; Mizokami M; Sureau C; Wakita T
    J Hepatol; 2017 Apr; 66(4):685-692. PubMed ID: 27890789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulation of HBV transcription by sodium taurocholate cotransporting polypeptide at the postentry step is inhibited by the entry inhibitor Myrcludex B.
    Zhao K; Liu S; Chen Y; Yao Y; Zhou M; Yuan Y; Wang Y; Pei R; Chen J; Hu X; Zhou Y; Zhao H; Lu M; Wu C; Chen X
    Emerg Microbes Infect; 2018 Nov; 7(1):186. PubMed ID: 30459339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary biliary acids inhibit hepatitis D virus (HDV) entry into human hepatoma cells expressing the sodium-taurocholate cotransporting polypeptide (NTCP).
    Veloso Alves Pereira I; Buchmann B; Sandmann L; Sprinzl K; Schlaphoff V; Döhner K; Vondran F; Sarrazin C; Manns MP; Pinto Marques Souza de Oliveira C; Sodeik B; Ciesek S; von Hahn T
    PLoS One; 2015; 10(2):e0117152. PubMed ID: 25646622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory effect of fasiglifam on hepatitis B virus infections through suppression of the sodium taurocholate cotransporting polypeptide.
    Nio Y; Akahori Y; Okamura H; Watashi K; Wakita T; Hijikata M
    Biochem Biophys Res Commun; 2018 Jun; 501(3):820-825. PubMed ID: 29723527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity.
    Wang XX; Wang D; Luo Y; Myakala K; Dobrinskikh E; Rosenberg AZ; Levi J; Kopp JB; Field A; Hill A; Lucia S; Qiu L; Jiang T; Peng Y; Orlicky D; Garcia G; Herman-Edelstein M; D'Agati V; Henriksen K; Adorini L; Pruzanski M; Xie C; Krausz KW; Gonzalez FJ; Ranjit S; Dvornikov A; Gratton E; Levi M
    J Am Soc Nephrol; 2018 Jan; 29(1):118-137. PubMed ID: 29089371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide.
    Kaneko M; Watashi K; Kamisuki S; Matsunaga H; Iwamoto M; Kawai F; Ohashi H; Tsukuda S; Shimura S; Suzuki R; Aizaki H; Sugiyama M; Park SY; Ito T; Ohtani N; Sugawara F; Tanaka Y; Mizokami M; Sureau C; Wakita T
    J Virol; 2015 Dec; 89(23):11945-53. PubMed ID: 26378168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP.
    Iwamoto M; Watashi K; Tsukuda S; Aly HH; Fukasawa M; Fujimoto A; Suzuki R; Aizaki H; Ito T; Koiwai O; Kusuhara H; Wakita T
    Biochem Biophys Res Commun; 2014 Jan; 443(3):808-13. PubMed ID: 24342612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemical array system, a platform to identify novel hepatitis B virus entry inhibitors targeting sodium taurocholate cotransporting polypeptide.
    Kaneko M; Futamura Y; Tsukuda S; Kondoh Y; Sekine T; Hirano H; Fukano K; Ohashi H; Saso W; Morishita R; Matsunaga S; Kawai F; Ryo A; Park SY; Suzuki R; Aizaki H; Ohtani N; Sureau C; Wakita T; Osada H; Watashi K
    Sci Rep; 2018 Feb; 8(1):2769. PubMed ID: 29426822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Semisynthetic bile acid FXR and TGR5 agonists: physicochemical properties, pharmacokinetics, and metabolism in the rat.
    Roda A; Pellicciari R; Gioiello A; Neri F; Camborata C; Passeri D; De Franco F; Spinozzi S; Colliva C; Adorini L; Montagnani M; Aldini R
    J Pharmacol Exp Ther; 2014 Jul; 350(1):56-68. PubMed ID: 24784847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide.
    Yan H; Peng B; Liu Y; Xu G; He W; Ren B; Jing Z; Sui J; Li W
    J Virol; 2014 Mar; 88(6):3273-84. PubMed ID: 24390325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irbesartan, an FDA approved drug for hypertension and diabetic nephropathy, is a potent inhibitor for hepatitis B virus entry by disturbing Na(+)-dependent taurocholate cotransporting polypeptide activity.
    Wang XJ; Hu W; Zhang TY; Mao YY; Liu NN; Wang SQ
    Antiviral Res; 2015 Aug; 120():140-6. PubMed ID: 26086883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetics of the bile acid transporter and hepatitis B virus receptor Na+/taurocholate cotransporting polypeptide (NTCP) in hepatocytes.
    König A; Döring B; Mohr C; Geipel A; Geyer J; Glebe D
    J Hepatol; 2014 Oct; 61(4):867-75. PubMed ID: 24845614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP).
    Watashi K; Sluder A; Daito T; Matsunaga S; Ryo A; Nagamori S; Iwamoto M; Nakajima S; Tsukuda S; Borroto-Esoda K; Sugiyama M; Tanaka Y; Kanai Y; Kusuhara H; Mizokami M; Wakita T
    Hepatology; 2014 May; 59(5):1726-37. PubMed ID: 24375637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor.
    Nkongolo S; Ni Y; Lempp FA; Kaufman C; Lindner T; Esser-Nobis K; Lohmann V; Mier W; Mehrle S; Urban S
    J Hepatol; 2014 Apr; 60(4):723-31. PubMed ID: 24295872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ergosterol peroxide inhibits HBV infection by inhibiting the binding of the pre-S1 domain of LHBsAg to NTCP.
    Huang H; Huang HC; Chiou WC; Lin LC; Chen JC; Liu HK; Lai YH; Huang C
    Antiviral Res; 2021 Nov; 195():105184. PubMed ID: 34627935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NTCP and beyond: opening the door to unveil hepatitis B virus entry.
    Watashi K; Urban S; Li W; Wakita T
    Int J Mol Sci; 2014 Feb; 15(2):2892-905. PubMed ID: 24557582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP.
    Donkers JM; Zehnder B; van Westen GJP; Kwakkenbos MJ; IJzerman AP; Oude Elferink RPJ; Beuers U; Urban S; van de Graaf SFJ
    Sci Rep; 2017 Nov; 7(1):15307. PubMed ID: 29127322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reciprocal regulation of farnesoid X receptor α activity and hepatitis B virus replication in differentiated HepaRG cells and primary human hepatocytes.
    Radreau P; Porcherot M; Ramière C; Mouzannar K; Lotteau V; André P
    FASEB J; 2016 Sep; 30(9):3146-54. PubMed ID: 27251172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.